Table 1.
Participant demographic and clinical characteristics
| PRF + ozone group (n=44) | Ozone group (n=47) | F/χ2 | P-value | |
|---|---|---|---|---|
| Age (yr) | 67.11±8.74 | 66.53±11.19 | 0.275 | 0.784 |
| Sex | 0.286 | 0.676 | ||
| Male | 20 | 24 | ||
| Female | 24 | 23 | ||
| Disease course (mon) | 12 (3–120) | 8 (3–360) | – | 0.314 |
| Affected side | 0.017 | 0.897 | ||
| Left | 24 | 25 | ||
| Right | 20 | 22 | ||
| Pain location | 5.057 | 0.281 | ||
| Face | 14 | 9 | ||
| Neck and upper limb | 5 | 5 | ||
| Chest and back | 21 | 21 | ||
| Abdomen | 2 | 7 | ||
| Waist | 2 | 5 | ||
| Number of ozone treatments | 7 (1–10) | 5 (1–16) | – | 0.068 |
| Pre-treatment VAS | 8 (4–10) | 8 (5–10) | – | 0.302 |
| Pre-treatment von Frey | 0.008 (0.008–60) | 0.008 (0.008–60) | – | 0.647 |
| History of underlying disease | ||||
| Hypertension | 14 | 17 | 0.192 | 0.662 |
| Type 2 diabetes | 11 | 5 | 3.235 | 0.072 |
Notes: Data in age are expressed as mean ± SD and were analyzed by independent samples t-test. Data in sex, affected side, pain location and history of underlying disease are expressed as number and were analyzed by Shapiro-Wilk test. Data in disease course, number of ozone treatments, pre-treatment VAS and pre-treatment von Frey are expressed as median (range) and were analyzed by Mann-Whitney U test. PRF: Pulsed radiofrequency; VAS: visual analog scale.